- 1 Use of U.S. Blood Donors for National Serosurveillance of SARS-CoV-2 Antibodies: Basis for an
- 2 Expanded National Donor Serosurveillance Program.
- 3
- 4 Mars Stone^{1,2}, Clara Di Germanio¹, David J. Wright³, Hasan Sulaeman¹, Honey Dave¹, Rebecca V.
- 5 Fink³, Edward P. Notari⁴, Valerie Green⁵, Donna Strauss⁶, Debra Kessler⁶, Mark Destree⁷, Paula Saa⁴,
- 6 Phillip C. Williamson^{1,5}, Graham Simmons^{1,2}, Susan L. Stramer⁴, Jean Opsomer³, Jefferson M. Jones⁸,
- 7 Steven Kleinman⁹, Michael P. Busch^{1,2}; for the NHLBI Recipient Epidemiology and Donor Evaluation
- 8 Study-IV-Pediatric (REDS-IV-P)
- 9 1. Vitalant Research Institute (VRI), San Francisco, CA
- 10 2. Department of Laboratory Medicine, University of California, San Francisco, CA
- 11 3. Westat, Rockville, MD
- 12 4. American Red Cross (ARC), Gaithersburg, MD
- 13 5. Creative Testing Solutions (CTS), Tempe, AZ
- 14 6. New York Blood Center (NYBC), New York, NY
- 15 7. BloodWorks Northwest, Seattle, WA
- 16 8. Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia
- 17 9. University of British Columbia, Victoria, BC, Canada
- 18
- 19 Corresponding author: Michael P. Busch MD, PhD. Address: Vitalant Research Institute, 270
- 20 Masonic Avenue, San Francisco, CA, United States 94118. Phone: 1-415-354-1389. Fax: 1-415-567-
- 21 5899. Email: mbusch@vitalant.org
- 22 Alternate corresponding author: Mars Stone, PhD. Vitalant Research Institute, 270 Masonic Avenue,
- 23 San Francisco, CA, United States 94118. Phone: 1-415-354-1389. Fax: 1-415-567-5899. Email:
- 24 <u>mstone@vitalant.org</u>
- 25 Keywords: SARS-CoV-2, COVID-19, seroprevalence, COVID-19 Serological Testing
- 26 Word count: 2965/3000

27	Summary: SARS-CoV-2 serosurveillance data from blood donors in 6 US regions were used
28	to estimate population weighted seroprevalence. Seroprevelance rates were higher in
29	younger, non-Hispanic Black, and Hispanic donors and correlated with reported regional
30	case rates. The study was expanded to a national donor serosurveillance program.
31	
32	Disclaimer: The content is solely the responsibility of the authors and does not represent the policy
33	of the National Institutes of Health or the Department of Health and Human Services. Any specific
34	brand names included in this manuscript are for identification purposes only and are not intended
35	to represent an endorsement by CDC. The findings and conclusions in this report are those of the
36	authors and do not necessarily represent the official position of the Centers of Disease Control and
37	Prevention.
38	
39	Abstract
40	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the Novel
40 41	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-
40 41 42	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the NovelSARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for SARS-CoV-2 antibodies on blood donors in six U.S. metropolitan
40 41 42 43	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the NovelSARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for SARS-CoV-2 antibodies on blood donors in six U.S. metropolitanregions to estimate the extent of SARS-COV-2 infections over time.
40 41 42 43 44	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the NovelSARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross- sectional testing for SARS-CoV-2 antibodies on blood donors in six U.S. metropolitanregions to estimate the extent of SARS-COV-2 infections over time.Study Design/Methods During March-August 2020, approximately ≥1,000 serum
40 41 42 43 44 45	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the NovelSARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for SARS-CoV-2 antibodies on blood donors in six U.S. metropolitanregions to estimate the extent of SARS-COV-2 infections over time.Study Design/Methods During March-August 2020, approximately ≥1,000 serumspecimens were collected monthly from each region and tested for SARS-CoV-2 antibodies
40 41 42 43 44 45 46	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross- sectional testing for SARS-CoV-2 antibodies on blood donors in six U.S. metropolitan regions to estimate the extent of SARS-COV-2 infections over time. Study Design/Methods During March-August 2020, approximately ≥1,000 serum specimens were collected monthly from each region and tested for SARS-CoV-2 antibodies using a well-validated algorithm. Regional seroprevalence estimates were weighted based
40 41 42 43 44 45 46 47	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the NovelSARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for SARS-CoV-2 antibodies on blood donors in six U.S. metropolitanregions to estimate the extent of SARS-COV-2 infections over time.Study Design/Methods During March-August 2020, approximately ≥1,000 serumspecimens were collected monthly from each region and tested for SARS-CoV-2 antibodiesusing a well-validated algorithm. Regional seroprevalence estimates were weighted basedon demographic differences with the general population. Seroprevalence was compared
40 41 42 43 44 45 46 47 48	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the NovelSARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for SARS-CoV-2 antibodies on blood donors in six U.S. metropolitanregions to estimate the extent of SARS-COV-2 infections over time.Study Design/Methods During March-August 2020, approximately ≥1,000 serumspecimens were collected monthly from each region and tested for SARS-CoV-2 antibodiesusing a well-validated algorithm. Regional seroprevalence estimates were weighted basedon demographic differences with the general population. Seroprevalence was comparedwith reported COVID-19 case rates over time.
40 41 42 43 44 45 46 47 48 49	Introduction: The REDS-IV-P Epidemiology, Surveillance and Preparedness of the NovelSARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for SARS-CoV-2 antibodies on blood donors in six U.S. metropolitanregions to estimate the extent of SARS-COV-2 infections over time.Study Design/Methods During March-August 2020, approximately ≥1,000 serumspecimens were collected monthly from each region and tested for SARS-CoV-2 antibodieson demographic differences with the general population. Seroprevalence was comparedwith reported COVID-19 case rates over time.Results/Findings: For all regions, seroprevalence was <1.0% in March 2020. New York

51 experienced modest increases in seroprevalence (1-2% in May-June to 2-4% in July-52 August). Seroprevalence was higher in younger, non-Hispanic Black, and Hispanic donors. 53 Temporal increases in donor seroprevalence correlated with reported case rates in each 54 region. In August, 1.3-5.6 estimated cumulative infections (based on seroprevalence data) 55 per COVID-19 case reported to CDC. 56 **Conclusion**: Increases in seroprevalence were found in all regions, with the largest 57 increase in New York. Seroprevalence was higher in non-Hispanic Black and Hispanic blood 58 donors than in non-Hispanic White blood donors. SARS-CoV-2 antibody testing of blood 59 donor samples can be used to estimate the seroprevalence in the general population by region and demographic group. The methods derived from the RESPONSE seroprevalence 60 61 study served as the basis for expanding SARS-CoV-2 seroprevalence surveillance to all 50 states and Puerto Rico. 62

63 Introduction

Globally, as of January 2021, SARS-CoV-2 has caused nearly 100 million diagnosed COVID-64 19 cases, over two million deaths, and a substantial number of infections that are either 65 asymptomatic or mildly symptomatic (1-3). With application of sensitive and specific 66 67 serological assays and algorithms to representative populations, SARS-CoV-2 serosurveys are critical for estimating total infection rates, infection fatality rates, extent of herd 68 69 immunity, and the effect of epidemic mitigation policies (4). Blood-donor-based 70 serosurveillance is a powerful and cost-effective strategy that has provided valuable 71 insights on infection prevalence and incidence for past emerging infectious threats 72 including West Nile Virus, dengue, chikungunya and Zika (5-10). Choice of assays for 73 serosurveillance should be determined by intended purpose (11, 12) and assay

74 performance which can be influenced by antigen and immunoglobulin targets, and assay

75 configuration (13).

76 In response to the emergence of COVID-19 in the United States in early 2020, the National

- 77 Heart, Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study
- 78 (REDS-IV-P) program developed and implemented molecular and serologic surveillance for
- 79 SARS-CoV-2 in six metropolitan regions, called the **R**EDS-IV-P **E**pidemiology, **S**urveillance
- and Preparedness of the Novel SARS-CoV-2 Epidemic (RESPONSE) study. RESPONSE
- 81 project aims included conducting testing for SARS-CoV-2 antibodies to estimate
- 82 seroprevalence, to evaluate trends in seroprevalence, and to compare the observed
- 83 seroprevalence with reported case data.

84 **METHODS**

85 Study Sites and Donation Sampling

The RESPONSE study tested for SARS-CoV-2 antibodies in three early-outbreak regions 86 87 starting in March 2020 (Seattle, New York, and San Francisco), and three initially low-88 prevalence regions in April 2020 (Boston, Los Angeles, and Minneapolis) (see Table 1 for 89 donor characteristics and Figure 1 for testing algorithm). About 1000 serum specimens 90 were randomly selected monthly from allogeneic blood donors from March/April through 91 August 2020. In July and August, monthly sampling increased to 2000-4000 per region as 92 the study transitioned into the expanded Multistate Assessment of SARS-CoV-2 93 Seroprevalence in Blood Donors (MASS-BD) Study (14). Beginning in June 2020, the blood collection organizations associated with four regions (San Francisco, Los Angeles, 94 95 Minneapolis, and Boston) began screening all blood donors for SARS-CoV-2 antibodies.(15) 96 In July and August in these regions, antibody data were extracted from donation records, whereas for Seattle and New York, study-initiated testing continued. For all months, 97

98	donations made specifically to provide COVID-19 convalescent plasma (CCP) were
99	excluded. The study was reviewed by the UCSF Committee for Human Research and
100	determined to meet the definition of research as defined in 46.102(l) but did not involve
101	human subjects based on anonymization of data and routine consent for blood donation
102	testing that includes use of residual samples for research purposes (as defined in
103	46.103(e)(1) consistent with applicable federal law and CDC policy (45 C.F.R. part 46; 21
104	C.F.R. part 56; 42 U.S.C. §241(d), 5 U.S.C. §552a, 44 U.S.C. §3501)). We used the STROBE
105	cross sectional checklist when writing our report. (16)
106	Screening and supplemental serology assays and establishing a testing algorithm
107	Initially, the serology screening and supplemental testing algorithm consisted of screening
108	all samples with the Ortho VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total test
109	(Vitros CoV2T). Reactive samples were confirmed by parallel testing by both a
110	nucleocapsid (NC)-based Total Ig assay (Roche Elecsys NC Anti-SARS-CoV-2 Total Ig)
111	(Elecsys CoV2T) and a pseudovirus reporter virus particle neutralization test (RVPN)
112	(Appendix A). Screened-positive specimens were considered confirmed if reactive by either
113	Elecsys CoV2T or RVPN. The Vitros CoV2T and Elecsys CoV2T assays were selected based
114	on their double antigen-sandwich design, which enables durable detection of total Ig and
115	employed as an orthogonal algorithm to detect antibodies to different SARS-CoV-2 antigens
116	(S1 and NC, respectively). FDA EUA Instructions for Use (IFU) (17) and other reports have
117	demonstrated excellent sensitivity of both assays during acute infection and stability of
118	antibody reactivity on serial samples collected >120 days from COVID-19 symptom onset.
119	(18-20)

120 Statistical methods to extrapolate donor seroprevalence to the general population

121 The geographic distribution and demographic composition of sampled donors varied 122 monthly. To ensure sample populations represented a consistent geographic area over the 123 course of the study, donations were restricted to ZIP codes in which at least 80% of donors resided, referred to in this study as the Donor Catchment Regions (DCRs). Donations from 124 125 donors that resided outside of the DCR were excluded. Monthly sample donor 126 demographics were compared with monthly total donation demographics at each blood 127 center via Chi-square statistics (without accounting for a multiple comparison adjustment) 128 to ensure that sampled donations were representative of general donor populations. 129 To estimate the monthly seroprevalence in the general population based on blood donor seroprevalence, monthly estimation weights were created that accounted for demographic 130 131 difference between the blood donor sample and general population. The 2018 American Community Survey (ACS) estimates (21) for the age, gender, and race/ethnicity 132 composition for the DCRs were used to standardize DCR sample totals by raking. In 133 134 addition to these estimation weights, monthly sets of 50 pseudo-replicate weights were 135 created to compute weighted seroprevalence standard errors. Because seroprevalence in 136 the U.S. population is known to vary by location and time, a stratified (by blood center and 137 month) logistic regression model was developed to assess the association between seropositivity and demographic characteristics. 138 139 Blood donation DCRs were defined by ZIP codes, but case reporting by state and local health departments to CDC is reported by county. Therefore, to compare the number of 140 cumulative infections estimated from seroprevalence with the number of cumulative cases 141 142 reported to CDC by each region, we created county-based DCRs. The number of total

143 cumulative infections in a DCR was estimated by multiplying the weighted seroprevalence

144 by the total population in the DCR. (See Supplemental Figure 1 and Appendix B for detailed

- 145 statistical methods). For each county-based DCR, the number of cumulative infections
- 146 based on seroprevalence was divided by the number of reported cases.
- 147

148 **RESULTS**

149 Validation of supplemental testing algorithm

During March-June 2020, a total of 21,485 donations were screened with Vitros CoV2T, of
which 489 reactive specimens were tested in parallel by the Elecsys CoV2T and RVPN

- **152** (Figure 1a). Specimens were stratified based on Vitros CoV2T signal to cutoff (S/CO)

ratios: specimens with S/CO 1-10 and specimens with S/CO \geq 10. Parallel testing of all

screened reactive specimens demonstrated that among the 404 specimens with Vitros

155 CoV2T S/CO ≥10.0 and available Elecsys CoV2T results, 384 were Elecsys CoV2T reactive

and 19 reactive by RVPN, thus >99% of specimens with Vitros CoV2T S/CO≥10 were

157 confirmed reactive by either Elecsys CoV2T or RVPN. In contrast, of 79 screened reactive

specimens with Vitros CoV2T S/CO 1-10 and available Elecsys CoV2T results, 29 were

159 Elecsys CoV2T reactive and 12 were RVPN reactive, only 51% of specimens with S/CO 1-10

160 were confirmed reactive (**Figure 1a**). Thus, beginning in July we modified the

161 supplemental testing algorithm to be more cost-effective while maintaining high sensitivity

and specificity for July and August (Figure 1b) so that specimens were considered

163 "confirmed antibody positive" if: i) they had a S/CO \geq 10 on Vitros CoV2T screening assay

164 (i.e., no supplemental testing was performed); or ii) if the Vitros CoV2T S/CO was 1–10

and reactive on either the Elecsys CoV2T or RVPN assay. Details and results of application

166 of this testing algorithm for the entire study interval (March-August) are presented in

167 Appendix C.

Seroprevalence estimates over time, with and without supplemental testing and population
weighting

170 In total, 499,476 non-COVID-19 convalescent plasma donations were collected in all 171 participating regions during the study period, of which 50,156 (10%) were included in the 172 study. Monthly distributions of Vitros CoV2T reactivity, supplemental testing status, and 173 number of tested specimens are shown in **Figure 2**, **Panel A**, and seroprevalence by month 174 and site are presented in Supplemental Table 2. Low rates of unweighted confirmed seroreactivity (<1%) were observed for all regions at the beginning of the testing period in 175 176 March 2020, with variable increases over the 5-6-month serosurveillance period. The greatest increase in seroprevalence was seen in New York (0.7% to 15.7%) followed by Los 177 178 Angeles (0.8% to 4.5%) and Boston (0.9% to 4.2%). Mean Vitros CoV2T signal intensity increased from a S/CO of 37.8 (range: 1.1-182.4) in March to 308.9 (range: 1.0-1380.0) in 179 180 August, demonstrating that both proportions of confirmed seropositive donations and 181 mean signal intensities increased over time in each region. 182 In **Figure 2**, **Panel B**, the screening and confirmed seroprevalence data are presented over time for each DCR. A high proportion of screen-reactive donations confirmed, particularly 183 184 in later months as seroprevalence increased; in July and August, 81-96% of specimens that screened reactive for anti-S antibodies by Vitros CoV2T were also reactive for anti-NC 185 186 antibodies by Elecsys CoV2T. Median weighted confirmed seroprevalence was 1.3 times higher than unweighted 187 confirmed seroprevalences (IOR 1.02-1.44). 188

189 Demographic, blood group and donation status associations with weighted seroprevalence
190 estimates

The confirmed, weighted seroprevalence estimates by donor demographic subcategories 191 192 (sex, age, race/ethnicity), and by blood groups (ABO and Rh) presented in **Table 2** were 193 restricted to August as the most recent findings in this study. For New York, Los Angeles 194 and Boston, sites with sufficient donations from racial and ethnic minority donors for 195 meaningful comparison, seroprevalence was higher among younger age groups and among 196 non-Hispanic Blacks and Hispanics than non-hispanic Whites. In New York in August, the 197 seroprevalence among Hispanics was 28.6%, among non-Hispanic Blacks was 16.0% and 198 among non-Hispanic Whites was 8.4%. 199 In a logistic regression model that included results from all regions and months, 200 seroprevalence was associated with younger age (p<0.0001): compared to persons aged 201 50-64 years, persons aged 16-29 years had 1.31 (CI 1.1-1.6) times the odds of being 202 seropositive. Both non-Hispanic Blacks (Odds ratio [OR] 2.2, 95% confidence interval [CI] 203 1.6-2.9) and Hispanics (OR 2.6, CI 2.2-3.1) had greater odds of being seropositive than non-204 Hispanic Whites (**Table 3**). Gender and blood types were not significantly associated with 205 seroprevalence. First-time donors had increased seroprevalence compared to repeat 206 donors (OR 2.2. CI: 1.6-3.2)). In the four regions where donors in July and August were 207 universally tested for SARS-CoV-2 antibodies, first-time donors had 2.2 (CI 1.8-2.6) times 208 the odds of being seropositive compared to repeat donors. In the two regions where blood 209 donors were not being offered antibody testing, first time donors had only 1.2 (CI 1.0-1.5) 210 times the odds of repeat donors. 211 *Comparison of monthly seroprevalence (as calculated from donor serosurveillance) with*

211 Comparison of monthly seroprevalence (as calculated from donor serosurveillance) with
 212 reported COVID-19 case rates

For each region, the monthly confirmed, weighted seroprevalence was juxtaposed with the weekly and cumulative COVID-19 case counts. Seroprevalence and cumulative COVID-19

215	case rates increased in all regions from March/April through August (Figure 3). New York
216	reported the highest seroprevalence, increasing from 0.7% in March to 13.2% in April,
217	corresponding with the sharp rise in reported New York COVID-19 cases. Coincident with a
218	decrease in daily reported cases from May through July, the seroprevalence in New York
219	stabilized at \sim 15-16% during this time, with smaller increases in other regions. The
220	cumulative case incidence for Boston and Los Angeles in July was similar to the cumulative
221	case incidence for New York in April (\sim 2,000 cumulative reported cases per 100,000
222	population), but seroprevalence for Boston and Los Angeles remained substantially lower
223	than New York.
224	The number of estimated cumulative infections, based on the adjusted donor
225	seroprevalence and population sizes, was larger than the number of cumulative reported
226	infections for all regions (Table 4). However, the ratio varied by region and over time. For
227	all cities except New York, much higher numbers of estimated infections per reported case
228	occurred in the first month of blood donor screening compared with later months. The
229	highest reported ratio of estimated infections to reported cases occurred in Minneapolis in
230	April (42 infections per reported case). By August 2020, all regions other than New York
231	had 1.6-3.2 estimated infections per reported case. During May through August, New York
232	had the highest number of estimated infections per reported case (5.3-6.4 infections per
233	reported case).
234	DISCUSSION

Use of blood donor populations with broad national representativeness provides a
surveillance tool to monitor seroprevalence and to impute infection rates within
communities, track outbreaks, and potentially correlate evolving infection rates with
pandemic mitigation measures.

239 Critical to the success of serosurveillance programs is the choice of SARS-CoV-2 antibody 240 assays and development and validation of supplemental testing algorithms. Antibody 241 persistence or waning has been shown to be assay-dependent (22), so it is essential to 242 select assays demonstrating durable antibody reactivity to accurately estimate cumulative 243 incidence based on serial cross-sectional seroprevalence data. Also important is the assay's 244 ability to sensitively detect antibodies following asymptomatic and mildly symptomatic 245 infections, which may produce weak systemic antibody responses (23). 246 The Vitros CoV2T and Elecsys CoV2T assays employed in this study satisfy many of these 247 criteria for serosurveillance assays: They have stable S/CO values over at least 4-5 months following seroconversion (20, 24) and have wide dynamic ranges, enabling implementation 248 249 of a screening assay S/CO threshold-based supplementary testing algorithm. By 250 demonstrating that >99% of specimens screened with Vitros CoV2T that had S/CO \geq 10 251 were also reactive by the Elecsys CoV2T or RVPN, we were able to adopt a robust and 252 lower-cost testing algorithm, limiting supplemental testing to screened specimens with 253 S/CO 1-10. This algorithm is now being employed by CDC's nationwide seroprevalence 254 blood donor study. To differentiate natural-infection-induced and vaccine-induced 255 seropositivity, the nationwide study is testing all anti-S-reactive specimens with an NC-256 based assay beginning in January 2021 (25). 257 Higher seroprevalence was observed in non-Hispanic Blacks and Hispanics than in non-258 Hispanic Whites in most regions but was particularly notable in New York. These racial 259 seroprevalence disparities are consistent with other reports (15, 26), potentially because 260 racial and ethnic minority groups experience inequities in access to health care, quality

housing, ability to work from home, and reliable transportation (27). Increased risk for

262 infection has been associated with younger age, possibly related to lack of adherence to

263 mitigation measures (15, 28). Future analyses will include comparing region-, age-, and
264 race/ethnicity-specific seroprevalence rates to the number of demographic group-specific
265 cumulative reported cases.

266 In this study, seroprevalence trends were consistent with the pattern of cumulative 267 reported COVID-19 cases. For most regions, the ratio of estimated infections to reported 268 cases was higher during March-April 2020 than in subsequent months. This suggests that 269 underreporting of COVID-19 cases to CDC was more severe during the earliest months of 270 the pandemic. Lack of available testing and avoiding medical care to obtain testing because 271 of COVID-19-related concerns might also have contributed (29). From May through August, 272 the calculated seroprevalence predicted 1.6-3.2 SARS-CoV-2 infections per cumulative case 273 reported to CDC for all regions except New York, which predicted 5.3-6.4 infections per

274 reported case.

275 Compared to the other large seroprevalence survey conducted by CDC using commercial 276 lab specimens, this study generally showed lower seroprevalence estimates (30). A 277 national seroprevalence study of dialysis patients with blood specimens collected during 278 July 2020 also reported generally higher seroprevalence estimates (31). Differences in the 279 geographic distribution of participants, serology assays used, and assumptions made when 280 extrapolating seroprevalence estimates to the general population may explain these 281 differences. Several local seroprevalence studies conducted in regions similar to the six 282 regions in this study have calculated similar or higher seroprevalence estimates (32-34). 283 However, many of these collected specimens were from healthcare workers or hospitalized 284 patients, who may be at higher risk of SARS-CoV-2 infection. 285 This study could have underestimated seroprevalence for several reasons. First, blood

286 donors may represent a population less likely to be exposed to SARS-CoV-2 than the

287 general population (35). Also, blood donors tend to be in better health than the general population and recruitment practices and eligibility criteria for blood donations may bias 288 289 the donor sample toward lower-risk individuals; this may explain the lower rates of 290 antibody positivity in repeat donors (who provide >80% of donations) compared to first 291 time donors. Secondly, many higher-risk populations cannot or do not donate, including 292 persons who are acutely febrile or ill, children aged <16 years, and institutionalized 293 persons such as those residing in nursing homes or prison. Third, compared to the general 294 population, relatively few ethnic and racial minorities donate, and these groups are at 295 increased risk for SARS-CoV-2 infection; this bias is partially compensated for because our 296 results were adjusted by weighting for race/ethnicity. Fourth, there is growing evidence 297 that approximately 5-10% of infected persons do not seroconvert (23). We did not adjust 298 our results to account for such "serosilent" infections. 299 Our results may overestimate seroprevalence because of implementation of SARS-CoV-2 300 antibody screening of all blood donations by some blood collection organizations in the 301 summer of 2020. These blood centers publicly advertised availability of this screening 302 which could have led to test seeking by prospective donors with increased concern over

303 exposure to the virus. However, our analysis of relative seroprevalence before and after

304 implementation of such "universal screening" in first time donors, who give 15-20% of

total donations, indicates that although the odds ratio was greater for first-time donors, the

impact of such test seeking was small relative to the expanding pandemic. Finally, there

307 was no formal process for randomization, however no bias was seen in comparison of

308 monthly samples with monthly donations (Supplemental Table 1).

305

Building on the approach developed in the RESPONSE seroprevalence study, in July 2020

310	the U.S. CDC funded a nationwide blood donor seroprevalence program that expanded this
311	surveillance program from six regions for 6 months to >60 U.S. regions with monthly
312	collections of 2,000-6,000 samples per region from July 2020 to December 2021
313	(Supplemental Figure 2). Similar to RESPONSE, changes in overall, geographic region-, age-,
314	sex-, and race/ethnicity-specific SARS-CoV-2 seroprevalence will be calculated monthly
315	over the course of the study and compared with clinical cases, deaths, and community
316	serosurvey data.
317	In conclusion, serial serosurveillance studies of SARS-CoV-2 using blood donor populations,
318	which are now being implemented in many countries (36), provide a powerful adjunct to
319	standard public health case reporting. Although serosurveillance data from asymptomatic
320	blood donors may lag behind viral transmission and case reporting by up to several weeks,
321	if appropriately designed, executed, analyzed, and interpreted, these studies will provide
322	urgently needed data to inform our understanding of the epidemiology and effectiveness of
323	responses to this unprecedented pandemic.
324	
325	
326	
327	Acknowledgments
328	The NHLBI REDS Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2
329	(RESPONSE) study is the responsibility of the following persons: Vitalant Research Institute M.P.
330	Busch, P.J. Norris, and M. Stone, Vitalant Research Institute, San Francisco, CA, Data coordinating
331	center; S.M. Mathew, Westat, Rockville, MD; Blood Collection Organizations: S. Stramer, American
332	Red Cross (ARC), Gaithersburg, MD, D. Kessler, New York Blood Center (NYBC), New York, NY, B.A.
333	Konkle, Blood Works Northwest, Seattle, WA, B. Custer, Vitalant Research Institute, San Francisco,

334	CA; Publications Co	ommittee Chairman:	P.M. Ness,	Johns Hop	okins University	<i>v</i> , Baltimore,	MD;
-----	---------------------	--------------------	------------	-----------	------------------	-----------------------	-----

- 335 Steering Committee Chairpersons: S.H. Kleinman, University of British Columbia, Victoria, BC,
- 336 Canada, C.D. Josephson, Emory University, Atlanta, GA, National Heart, Lung, and Blood Institute,
- 337 National Institutes of Health, S.A. Glynn and K. Malkin.

338

- 339 The authors thank C. Cassetti, National Institute of Allergies and Infectious Diseases (NIAID) and J.
- Jones, S. Gerber, M. Patton, F. Havers and S. Basavaraju of the Centers for Disease Control and
- 341 Prevention (CDC) for their technical support, as well as A.E. Williams and S. Anderson of the U.S.
- 342 Food and Drug Administration (FDA), J. Haynes from ARC for their contribution of data from the
- 343 Transfusion-Transmissible Infections Monitoring System (TTIMS) and L. McCain, A. Hui, C. Samuels,
- H. Tanner and Z. Kaidarova of Vitalant Research Institute for their technical assistance.

- **Funding source:** The authors were supported by research contracts from the National Heart, Lung,
- and Blood Institute (NHLBI Contracts HHSN 75N92019D00032 and HHSN 75N92019D00033) as
- 348 well as with funding support from the National Institute of Allergies and Infectious Diseases
- 349 (NIAID), NIH.

350 <u>References</u>

3511.European Centre for Disease Prevention and Control: COVID-19 situation update352worldwide, as of 14 July 2020 2020. Available from:

353 <u>https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.</u>

Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang
 F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. Clinical and immunological assessment
 of asymptomatic SARS-CoV-2 infections. Nature medicine. 2020. Epub 2020/06/20. doi:

357 10.1038/s41591-020-0965-6. PubMed PMID: 32555424.

- 358 3. Rothe C SM, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C,
- Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wolfel R, Hoelscher
 M. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. The New

361 England journal of medicine. 2020;382(20):970-2. Epub 2020/02/01.

Cohn J. Unprecedented nationwide blood studies seek to track U.S. coronavirus spread.
 Science. 2020. doi: doi:10.1126/science.abc1319.

Williamson PC, Linnen JM, Kessler DA, Shaz BH, Kamel H, Vassallo RR, Winkelman V, Gao
K, Ziermann R, Menezes J. First cases of Zika virus–infected US blood donors outside states with
areas of active transmission. Transfusion. 2017;57(3pt2):770-8.

Stone M, Bakkour S, Lanteri MC, Brambilla D, Simmons G, Bruhn R, Kaidarova Z, Lee T-H,
 Orlando Alsina J, Williamson PC, Galel SA, Pate LL, Linnen JM, Kleinman S, Busch MP. Zika virus
 RNA and IgM persistence in blood compartments and body fluids: a prospective observational
 study. The Lancet infectious diseases. 2020;20(12):1446-56. doi: 10.1016/s1473-

371 3099(19)30708-x.

372 7. Busch MP, Sabino EC, Brambilla D, Lopes ME, Capuani L, Chowdhury D, McClure C,
373 Linnen JM, Prince H, Simmons G, Lee TH, Kleinman S, Custer B, International Component of the
374 NRE, Donor Evaluation S, III. Duration of Dengue Viremia in Blood Donors and Relationships
375 Between Donor Viremia, Infection Incidence and Clinical Case Reports During a Large Epidemic.
376 The Journal of infectious diseases. 2016;214(1):49-54. doi: 10.1093/infdis/jiw122. PubMed
377 PMID: 27302934; PMCID: PMC4907419.

Lanteri MC, Lee TH, Wen L, Kaidarova Z, Bravo MD, Kiely NE, Kamel HT, Tobler LH, Norris
 PJ, Busch MP. West Nile virus nucleic acid persistence in whole blood months after clearance in
 plasma: implication for transfusion and transplantation safety. Transfusion. 2014;54(12):3232 41. doi: 10.1111/trf.12764. PubMed PMID: 24965017; PMCID: PMC4268370.

382 9. Simmons G, Bres V, Lu K, Liss NM, Brambilla DJ, Ryff KR, Bruhn R, Velez E, Ocampo D,

Linnen JM, Latoni G, Petersen LR, Williamson PC, Busch MP. High Incidence of Chikungunya

Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014.

385 Emerg Infect Dis. 2016;22(7):1221-8. doi: 10.3201/eid2207.160116. PubMed PMID: 27070192;
 386 PMCID: PMC4918147.

387 10. Saa P, Proctor M, Foster G, Krysztof D, Winton C, Linnen JM, Gao K, Brodsky JP,

Limberger RJ, Dodd RY, Stramer SL. Investigational Testing for Zika Virus among U.S. Blood

Donors. The New England journal of medicine. 2018;378(19):1778-88. doi:

390 10.1056/NEJMoa1714977. PubMed PMID: 29742375.

391 11. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020;323(22):2249-51 doi: 10.1001/jama.2020.8259

393 Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang 12. 394 L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. Profiling Early 395 Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020. 396 Epub 2020/03/22. doi: 10.1093/cid/ciaa310. PubMed PMID: 32198501. 397 Che XY QL, Liao ZY, Wang YD, Wen K, Pan YX, Hao W, Mei YB, Cheng VC, Yuen KY. 13. 398 Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus 399 and human coronaviruses 229E and OC43. The Journal of infectious diseases. 400 2020;191(12):2033-7. 401 14. Centers for Disease Control and Prevention. Multistate Assessment of SARS-CoV-2 402 Seroprevalence in Blood Donors https://www.cdc.gov/coronavirus/2019-ncov/cases-403 updates/blood-bank-serosurvey.html2020 [updated Nov. 13, 2020]. 404 Dodd R, Xu M, Stramer SL. Change in Donor Characteristics and Antibodies to SARS-CoV-15. 405 2 in Donated Blood in the US, June-August, JAMA, 2020. Epub Published online September 14, 406 2020. 407 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The 16. 408 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: 409 guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-9. Epub 410 2008/03/04. doi: 10.1016/j.jclinepi.2007.11.008. PubMed PMID: 18313558. 411 U.S. Food & Drug Administration. EUA Authorized Serology Test Performance 2020 17. 412 [February 9, 2021]. Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-413 414 performance. 415 18. Zilla M, Wheeler BJ, Keetch C, Mitchell G, McBreen J, Wells A, Shurin MR, Peck-Palmer 416 O, Wheeler SE. Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect 417 Convalescent Plasma and Seroprevalence Screening. Am J Clin Pathol. 2020. Epub 2020/11/07. 418 doi: 10.1093/ajcp/agaa228. PubMed PMID: 33155015. 419 Grandjean L, Saso A, Ortiz A, Lam T, Hatcher J, Thistlethwaite R, Harris M, Best T, 19. 420 Johnson M, Wagstaffe H, Ralph E, Mai A, Colijn C, Breuer J, Buckland M, Gilmour K, Goldblatt D. 421 Humoral Response Dynamics Following Infection with SARS-CoV-2. medRxiv. 422 2020:2020.07.16.20155663. doi: 10.1101/2020.07.16.20155663. 423 Clara Di Germanio CD, Simmons G, Kelly K, Martinelli R, Darst O, Azimpouran M, Stone 20. 424 M, Hazegh K, Grebe E, Zhang S, Ma P, Orzechowski M, Livny J, Hung DT, Vassallo RR, Busch MP, 425 Dumont LJ. SARS-CoV-2 Antibody persistence in COVID-19 convalescent plasma donors. 426 medRxiv preprint. 2021. Epub March 26, 2021. doi: 10.1101/2021.03.24.21254260. 427 21. American Community Survey (ACS) https://www.census.gov/programs-428 surveys/acs2018. 429 22. Buss LF, Prete CA, Abrahim CMM, Mendrone A, Salomon T, de Almeida-Neto C, França 430 RFO, Belotti MC, Carvalho MPSS, Costa AG, Crispim MAE, Ferreira SC, Fraiji NA, Gurzenda S, 431 Whittaker C, Kamaura LT, Takecian PL, da Silva Peixoto P, Oikawa MK, Nishiya AS, Rocha V, 432 Salles NA, de Souza Santos AA, da Silva MA, Custer B, Parag KV, Barral-Netto M, Kraemer MUG, 433 Pereira RHM, Pybus OG, Busch MP, Castro MC, Dye C, Nascimento VH, Faria NR, Sabino EC. Three-guarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated 434 435 epidemic. Science. 2021;371(6526):288-92. doi: 10.1126/science.abe9728. 436 Petersen LR, Sami S, Vuong N, Pathela P, Weiss D, Morgenthau BM, Henseler RA, 23. 437 Daskalakis DC, Atas J, Patel A, Lukacs S, Mackey L, Grohskopf LA, Thornburg N, Akinbami LJ. Lack

of antibodies to SARS-CoV-2 in a large cohort of previously infected persons. Clinical Infectious 438 439 Diseases. 2020. doi: 10.1093/cid/ciaa1685. 440 24. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter 441 SE, Thanh C, Nixon CC, Hoh R, Tai V, Fehrman E, Hernandez Y, Spinelli MA, Gandhi M, Palafox 442 M-A, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petropoulos CJ, Chiu CY, Norris 443 PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, 444 Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-445 Barraguer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by 446 disease severity, timing, and assay. medRxiv. 2021:2021.03.03.21251639. doi: 447 10.1101/2021.03.03.21251639. 448 Moore JP, Offit PA. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. 25. 449 JAMA. 2021. doi: 10.1001/jama.2021.1114. 450 Mackey K, Avers CK, Kondo KK, Saha S, Advani SM, Young S, Spencer H, Rusek M, 26. 451 Anderson J, Veazie S, Smith M, Kansagara D. Racial and Ethnic Disparities in COVID-19-Related 452 Infections, Hospitalizations, and Deaths: A Systematic Review. Ann Intern Med. 2020. Epub 453 2020/12/01. doi: 10.7326/M20-6306. PubMed PMID: 33253040; PMCID: PMC7772883. 454 Centers for Disease Control and Prevention. COVID-19 Racial and Ethnic Health 27. 455 Disparities 2020; December 10: 456 Centers for Disease Control and Prevention. COVID-19 Mitigation Behaviors by Age 28. Group — United States, April–June 2020. Morbidity and Mortality Weekly Report (MMWR). 457 2020;69(43):1584-90. Epub October 30, 2020 458 459 Czeisler MÉ, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, Ali N, McMillan H, 29. 460 Wiley JF, Weaver MD, Czeisler CA, Rajaratnam SMW, Howard ME. Delay or Avoidance of 461 Medical Care Because of COVID-19-Related Concerns -United States, June 2020. MMWR 462 Recommendations and reports : Morbidity and mortality weekly report Recommendations and 463 reports / Centers for Disease Control. 2020;63(36):1250-7. 464 Centers for Disease Control and Prevention: Commercial laboratory seroprevalence 30. survey data https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-465 surveys.html#surveymap2020 [January 12, 2021]. 466 467 Anand S, Montez-Rath M, Han J, Bozeman J, Kerschmann R, Beyer P, Parsonnet J, 31. 468 Chertow GM. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on 469 dialysis in the USA: a cross-sectional study. The Lancet. 2020;396(10259):1335-44. doi: 470 10.1016/S0140-6736(20)32009-2. 471 Mansour M, Leven E, Muellers K, Stone K, Mendu DR, Wajnberg A. Prevalence of SARS-32. CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City. 472 473 J Gen Intern Med. 2020;35(8):2485-6. Epub 2020/06/05. doi: 10.1007/s11606-020-05926-8. 474 PubMed PMID: 32495088; PMCID: PMC7269421. Morcuende M, Guglielminotti J, Landau R. Anesthesiologists' and Intensive Care 475 33. Providers' Exposure to COVID-19 Infection in a New York City Academic Center: A Prospective 476 477 Cohort Study Assessing Symptoms and COVID-19 Antibody Testing. Anesth Analg. 478 2020;131(3):669-76. Epub 2020/06/11. doi: 10.1213/ANE.0000000000005056. PubMed PMID: 479 32520728; PMCID: PMC7302070. 480 34. Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA, 481 McMahon M, Jhang J, Nowak MD, Simon V, Sordillo EM, Bakel Hv, Krammer F. Seroconversion

482 of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City. medRxiv.
483 2020:2020.06.28.20142190. doi: 10.1101/2020.06.28.20142190.

484 35. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, Fry AM, Cannon DL, Chiang

485 C-F, Gibbons A, Krapiunaya I, Morales-Betoulle M, Roguski K, Rasheed MAU, Freeman B, Lester

486 S, Mills L, Carroll DS, Owen SM, Johnson JA, Semenova V, Blackmore C, Blog D, Chai SJ, Dunn A,

487 Hand J, Jain S, Lindquist S, Lynfield R, Pritchard S, Sokol T, Sosa L, Turabelidze G, Watkins SM,

488 Wiesman J, Williams RW, Yendell S, Schiffer J, Thornburg NJ. Seroprevalence of Antibodies to

489 SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine.

490 2020;180(12):1576-86. doi: 10.1001/jamainternmed.2020.4130.

- 491 36. Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, Sækmose SG,
- 492 Nilsson AC, Brooks PT, Boldsen JK, Mikkelsen C, Gybel-Brask M, Sørensen E, Dinh KM, Mikkelsen
- 493 S, Møller BK, Haunstrup T, Harritshøj L, Jensen BA, Hjalgrim H, Lillevang ST, Ullum H. Estimation
- 494 of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clinical
- 495 infectious diseases : an official publication of the Infectious Diseases Society of America.
- 496 2020:ciaa849. doi: 10.1093/cid/ciaa849. PubMed PMID: 32584966.

Tables and Figures

				New Y	ork Sa	n Francisco	S	eattle	Bo	ston	Los Ang	eles	Minneapolis	All F	Regions
		All Donations	Sampled Donations												
All		131622	9132	28758	7986	76209	8019	47437	6999	114692	11000	98010	7000	496728	50156
Gender															
	Female	46.5	47.5	51.6	50.8	56.7	55.7	53.6	53.8	54.7	54.1	57.5	57.8	53.1	53.1
	Male	53.5	52.5	48.4	49.2	43.3	44.3	46.4	46.2	45.3	45.9	42.5	42.2	46.9	46.9
Age															
	16-29	18.0	20.5	12.5	11.8	14.4	13.1	13.6	14.4	16.3	16.4	10.8	9.8	14.9	14.7
	30-49	30.2	31.2	30.8	32.0	34.2	32.6	28.5	29.1	35.5	36.3	28.2	29.0	31.5	32.1
	50-64	38.8	34.5	36.9	36.1	32.2	32.6	40.3	39.2	34.5	34.3	36.1	36.7	36.3	35.4
	65+	13.0	13.8	19.8	20.2	19.2	21.7	17.6	17.2	13.7	13.1	24.9	24.5	17.3	17.9
Race/ Ethnicity															
	White	78.5	77.3	71.3	71.3	81.2	83.8	92.6	92.7	62.4	60.5	97.0	97.0	79.8	78.6
	Black	3.6	3.8	1.4	1.4	0.9	0.7	1.0	1.0	2.1	2.2	0.3	0.3	1.8	1.7
	Hispanic	8.9	8.0	8.2	8.4	2.4	2.3	2.0	2.2	19.9	20.8	0.8	0.7	8.1	8.1
	Other	8.9	10.9	19.2	18.8	15.6	13.2	4.4	4.1	15.7	16.4	1.9	2.0	10.3	11.6
Blood group															
	0	50.9	49.4	48.6	48.2	50.4	52.0	51.2	51.6	50.7	50.6	47.5	47.3	50.0	49.9
	A	32.6	33.5	33.7	34.4	35.3	34.9	33.2	33.1	32.8	32.4	37.3	37.0	34.1	34.1
	В	12.3	12.5	12.2	12.4	10.3	9.9	11.2	10.7	11.9	12.3	10.6	11.0	11.4	11.6
	AB	4.2	4.5	5.5	5.0	4.1	3.1	4.4	4.6	4.6	4.7	4.6	4.6	4.4	4.4
Rh type															
	Rh positive	83.3	84.2	83.0	83.5	79.9	79.2	80.7	80.5	84.7	84.5	78.5	77.9	81.9	81.9
Daman	Rh negative	16.7	15.8	17.0	16.5	20.1	20.7	19.3	19.4	15.3	15.5	21.4	22.1	18.1	18.0
Donor Status						·	·							·	·
	First time	14.6	14.8	28.4	18.0	21.1	16.2	22.8	21.8	30.9	27.3	18.0	16.2	21.6	19.5
	Repeat	85.4	85.2	71.6	82.0	78.9	83.8	77.2	78.2	69.1	72.7	82.0	83.8	78.4	80.5

Table 1. Demographic characteristics of donors that provided specimens included in study and of all donors who donated in each region, six U.S.metropolitan regions, March-August 2020. Rh = rhesus factor.

	Region							
Variable	es			Seroprevalence	(95% CI)			
		New York	San Francisco	Seattle	Los Angeles	Boston	Minneapolis	
		15.7 (13.6, 18.0)	1.5 (0.6, 3.1)	1.9 (1.2, 2.9)	4.5 (3.8, 5.3)	4.2 (2.8, 6.0)	1.5 (0.9, 2.3)	
Age								
	16-29	18.4 (13.9, 23.7)	4.1 (0.7, 12.2)	1.9 (0.4, 5.2)	8.0 (5.9 <i>,</i> 10.7)	5.6 (2.5, 10.3)	2.1 (0.5, 5.7)	
	30-49	17.4 (13.7, 21.6)	0.8 (0.2, 2.2)	1.7 (0.6, 3.9)	4.8 (3.4, 6.6)	3.4 (1.1, 7.7)	1.7 (0.7, 3.6)	
	50-64	14.9 (10.8, 19.8)	0.5 (0.1, 1.6)	2.5 (1.0, 5.2)	2.4 (1.4, 3.8)	5.1 (3.2, 7.8)	1.2 (0.4, 2.5)	
	65+	10.2 (5.3, 17.3)	0.9 (0.1, 3.3)	1.2 (0.3, 3.3)	1.2 (0.4, 2.8)	2.6 (1.2, 5.1)	0.6 (0.1, 2.1)	
Gender								
	Female	16.8 (13.8, 20.2)	1.9 (0.4 <i>,</i> 5.5)	2.0 (1.1, 3.6)	5.6 (4.4, 7.0)	4.2 (2.2, 7.2)	0.9 (0.3, 1.8)	
	Male	14.5 (11.6, 17.8)	1.1 (0.5, 2.1)	1.7 (0.8, 3.2)	3.4 (2.3, 4.7)	4.2 (2.6, 6.4)	2.1 (1.1, 3.6)	
Race								
	White	8.4 (7.1, 9.8)	1.6 (0.8, 3.0)	2.5 (1.5 <i>,</i> 3.9)	2.1 (1.5, 2.8)	2.9 (2.1, 3.8)	1.8 (1.1, 2.8)	
	Black	16.0 (9.6, 24.4)	0.0 (0.0, 15.8)	0.0 (0.0, 20.0)	3.1 (0.5, 9.2)	16.6 (3.8, 40.5)	0.0 (0.0, 60.0)	
	Hispanic	28.6 (22.1, 35.8)	2.8 (0.2, 11.3)	0.0 (0.0, 5.8)	6.9 (5.2, 8.9)	8.7 (2.1, 22.3)	0.0 (0.0, 21.4)	
	Other	13.0 (9.7, 16.9)	0.6 (0.0, 2.7)	0.5 (0.0, 3.3)	3.8 (2.3, 6.0)	5.6 (1.1, 16.0)	0.0 (0.0, 8.8)	
Blood Ty	ре							
	А	12.4 (8.9, 16.7)	2.2 (0.2, 8.7)	1.6 (0.8, 3.1)	3.1 (2.1, 4.4)	4.0 (2.3 <i>,</i> 6.5)	1.6 (0.7, 3.1)	
	AB	23.1 (11.4, 38.9)	3.1 (0.1, 16.7)	2.4 (0.1, 10.4)	4.0 (1.0, 10.3)	5.5 (0.3, 22.7)	2.0 (0.0, 10.8)	
	В	15.8 (9.2, 24.6)	1.2 (0.1, 4.3)	2.7 (0.3, 9.3)	4.1 (2.2, 6.9)	4.9 (1.6, 11.2)	2.7 (0.4, 8.5)	
	0	17.1 (13.5, 21.2)	1.0 (0.3, 2.3)	1.8 (0.8, 3.4)	5.4 (4.3, 6.6)	4.0 (2.2 <i>,</i> 6.6)	1.0 (0.4, 2.1)	
Rh type								
	Rh positive	16.1 (13.6, 18.7)	1.6 (0.6, 3.4)	1.9 (1.1, 3.1)	4.9 (4.1, 5.8)	4.4 (2.9 <i>,</i> 6.4)	1.3 (0.7, 2.4)	
	Rh negative	13.4 (8.9, 19.0)	0.9 (0.0, 3.9)	1.7 (0.3, 5.1)	1.6 (0.5, 3.7)	3.1 (0.9, 7.7)	2.1 (0.9, 4.1)	

Table 2. Weighted confirmed seroprevalence by demographic characteristics, six U.S. metropolitan regions, August 2020.

95% CI = 95% confidence interval; DCR = donor catchment region; Rh +ve = rhesus factor positive; Rh-ve = rhesus factor negative

(Characteristic	Odds Ratio (95%Cl)	p-value
Gena	ler		0.22
	Female	1 (reference)	
	Male	0.93 (0.82, 1.05)	
Age			<0.0001
	16-29	1.31 (1.11, 1.55)	
	30-49	1.12 (0.97, 1.30)	
	50-64*	1 (reference)	
	65+	0.66 (0.53, 0.83)	
Race,	/Ethnicity		< 0.0001
	White	1 (reference)	
	Black	2.16 (1.64, 2.85)	
	Hispanic	2.57 (2.17, 3.05)	
	Other	1.16 (0.96, 1.41)	
Blood	d Type		0.29
	A	1.11 (0.97, 1.26)	
	AB	1.21 (0.91, 1.61)	
	В	1.00 (0.82, 1.21)	
	0	1 (reference)	
Rh ty	pe		0.69
	Rh negative	1.03 (0.88, 1.22)	
	Rh positive	1 (reference)	
Dond	ition Type		< 0.0001
	First time	2.24 (1.58, 3.16)	
	repeat	1 (reference)	

Table 3. Factors associated with SARS-CoV-2 seropositivity in blood donors, six U.S. metropolitan regions, March–August 2020. 95% CI =

95% confidence interval. Rh = rhesus factor. *Reference 50-64 as the age group with highest frequency of donations

Region	Month	Seroprevalence	Estimated number of cumulative infections*	Cumulative reported cases†	Estimated number of infections per reported case‡
		Seroprevalence (95% CI)	No. (95% CI)	No.	Ratio (95% CI)
New York					
	March	0.71 (0.27–1.82)	129184 (49126 – 331148)	34562	3.7 (1.4–9.6)
	April	13.22 (9.27–18.5)	2405373 (1686672–3366067)	349083	6.9 (4.8–9.6)
	May	4 (12.19–20.14)	2867525 (2217965–3664465)	445202	6.4 (5.0–8.2)
	June	14.97 (11.08–19.93)	2723785 (2016001–3626255)	473521	5.8 (4.3–7.7)
	July	14.45 (10.87–18.96)	2629171 (1977792–3449764)	494591	5.3 (4.0–7.0)
	August	15.73 (13.68–18.03)	2862067 (2489070–3280551)	508746	5.6 (4.9–6.4)
San Francisco					
	March	0.11 (0.01–0.82)	8513 (773–63462)	624	13.6 (1.2–101.7)
	April	0.15 (0.03–0.76)	11609 (2321–58819)	6035	1.9 (0.4–9.7)
	May	0.44 (0.19–1.01)	34053 (14704–78167)	8980	3.8 (1.6–8.7)
	June	1.13 (0.36–3.49)	87454 (27861–270104)	15829	5.5 (1.8–17.1)
	July	0.91 (0.51–1.62)	70428 (39470–125377)	38667	1.8 (1.0–3.2)
	August	1.48 (0.7–3.11)	114542 (54175–240694)	65403	1.8 (0.8–3.7)
Seattle					
	March	0.18 (0.04–0.77)	8824 (1961–37751)	262	33.7 (7.5–144.1)
	April	1.01 (0.39–2.6)	49517 (19120–127471)	6410	7.7 (3.0–19.9)
	May	0.97 (0.43–2.16)	47556 (21081–105899)	12618	3.8 (1.7–8.4)
	June	1.75 (0.69–4.34)	85798 (33828–212779)	14973	5.7 (2.3–14.2)
	July	1.4 (0.9–2.17)	68638 (44124–106389)	23920	2.9 (1.8–4.4)
	August	1.87 (1.22–2.87)	91681 (59813–140708)	35170	2.6 (1.7–4.0)
Boston					
	April	0.86 (0.24–3.06)	54284 (15149–193152)	12677	4.3 (1.2–15.2)
	May	1.37 (0.7–2.67)	86476 (44185–168534)	63678	1.4 (0.7–2.6)
	June	2.3 (1.19–4.41)	145179 (75114–278366)	101040	1.4 (0.7–2.8)
	July	3.78 (2.71–5.25)	238599 (171059–331388)	108209	2.2 (1.6–3.1)

	August	4.21 (2.93–6.02)	265741 (184946–379992)	117279	2.3 (1.6–3.2)
Los Angeles					
	April	0.79 (0.3–2.04)	147820 (56134–381713)	7303	20.2 (7.7–52.3)
	May	0.68 (0.25–1.82)	127237 (46778–340548)	50077	2.5 (0.9–6.8)
	June	1.61 (0.78–3.3)	301254 (145949–617477)	87888	3.4 (1.7–7.0)
	July	2.39 (1.71–3.32)	447203 (319965–621219)	211358	2.1 (1.5–2.9)
	August	4.5 (3.81–5.3)	842014 (712905–991706)	347083	2.4 (2.1–2.9)
Minneapolis					
	April	0.67 (0.12–3.74)	36579 (6551–204192)	875	41.8 (7.5–233.4)
	May	0.54 (0.16–1.76)	29482 (8735–96090)	12357	2.4 (0.7–7.8)
	June	0.69 (0.22–2.17)	37671 (12011–118475)	25883	1.5 (0.5–4.6)
	July	1.78 (0.83–3.79)	97182 (45315–206921)	40927	2.4 (1.1–5.1)
	August	1.47 (0.93–2.33)	80257 (50775–127210)	60502	1.3 (0.8–2.1)

Table 4. Monthly seroprevalence, estimated number of cumulative infections, cumulative reported COVID-19 cases, and the estimated

number of cumulative infections per reported case, six U.S. metropolitan regions, March–August 2020. 95% CI = 95% confidence interval

*Confirmed seroprevalence multiplied by the region population size.

†Number reported to CDC.

[‡]Number of estimated infections divided by the number of cumulative reported cases.



Figure 1. SARS-CoV-2 serology testing results flow chart, six U.S. metropolitan regions. Panel A: Parallel testing using Elecsys CoV2T and RVNPT assay on Ortho Vitros S1 Total Ig CoV2T reactive samples collected during March–June 2020. Panel B: Results from March through August 2020 combining the initial and revised supplementary testing algorithms.

Vitros COV2T: Ortho VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total; QNS: quantity not sufficient; Elecsys CoV2T:

Roche Elecsys Nucleocapsid Anti-SARS-CoV-2 Total Immunoglobulin; RVPN: pseudovirus reporter virus particle

neutralization; R: reactive; NR: nonreative.

















weighted cumulative seroprevalence (panel B), six U.S. metropolitan regions March-August 2020. Panel A: Red lines indicate the Vitros CoV2T signal to cutoff value for reactivity (S/CO ratio = 1.0; Log₁₀ S/CO ratio = 0). Black symbols indicate confirmed reactive samples based on the study algorithm and black lines indicate the mean signal intensity of the Vitros CoV2T reactive donation samples for each region for each month of the study. Grey symbols above the Vitros CoV2T cutoff threshold indicate samples that were reactive by the Vitros CoV2T screening assay but which did not confirm using the study algorithm. Grey symbols below the red line indicate samples that were nonreactive on the Vitros CoV2T assay. The open black symbol (Seattle panel, June column) indicates the only sample with Vitros

CoV2T S/CO >10 which did not confirm. N= Number of sampled donations for each month. Panel B: Screened and confirmed, and confirmed restricted to ZIP code of residence seroprevelence for each region.



Figure 3. Weighted confirmed SARS-CoV-2 seroprevalence derived from blood donors (A), reported COVID-19 case rates per 100,000 population* (B), and daily COVID-19 case rates per 100,000* (C) in six U.S. metropolitan regions, March–August 2020.

*Reported COVID-19 cases reported to CDC.